Biopharma QC labs lag in digital maturity, Veeva analysis finds

• Veeva Systems' Oct. 22, 2026, analysis found biopharma quality-control labs lag R&D and manufacturing in operational maturity.
• Paper records and disconnected data ranked as the biggest efficiency drains, delaying batch approvals and product release.
• Budget constraints, cultural resistance and complex legacy systems impede modernization; custom integrations require substantial investment and costly maintenance.
• Weak integration with quality management slows deviation resolution, while disconnected on-premises systems make multisite changes expensive and risky.
• Faster-moving companies are positioning labs as strategic functions to secure funding, prioritizing cloud-based systems within unified quality strategies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veeva Systems Inc. published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.